MAP2K7 and melanoma: Compared to other real-world studies, Moser et al. [15] suggested a 34% and 49% mortality risk reduction in patients with BRAF-mutant advanced melanoma who received first-line dual IO versus BRAF + MEK inhibitor and first-line single-agent anti-PD1 versus BRAF + MEK inhibitor, respectively.